For Immediate Release
Chicago, IL – January 08, 2015 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Kite Pharma (KITE-Free Report), Isis Pharmaceuticals (ISIS-Free Report), Alkermes (ALKS-Free Report), Amgen (AMGN-Free Report) and Biogen (BIIB-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
Biotech Stock Roundup
The biotech sector has started 2015 with the announcement of several deals. Both Kite Pharma (KITE-Free Report) and Isis Pharmaceuticals (ISIS-Free Report) saw their share prices increasing on collaboration agreements with major companies. Meanwhile, Alkermes (ALKS-Free Report) has also started the year on a positive note with encouraging pipeline data.
Recap of the Week’s Most Important Stories
1. Alkermes started the new year on a positive note with the company hitting a 52-week high on positive topline results from a study being conducted on ALKS 5461, its experimental treatment for major depressive disorder. The data supports the company’s pivotal program for ALKS 5461. Results are encouraging with ALKS 5461 significantly reducing depressive symptoms from baseline. ALKS 5461 is one of the most interesting and promising candidates in the company’s pipeline. Alkermes has several more data-readouts lined up for 2015.
2. Kite Pharma is flying high on an agreement with biotech major, Amgen (AMGN-Free Report), targeting the development and commercialization of the next generation of novel chimeric antigen receptor (CAR) T cell immunotherapies. Amgen, given its expertise and focus on cancer treatments, is a suitable partner for Kite. The collaboration also drives home the growing interest in CAR T treatments (Read more: Kite Pharma Up on Amgen Cancer Immunotherapy Tie-Up).
3. Isis, which has collaboration agreements with several big names like Biogen (BIIB-Free Report), GlaxoSmithKline and AstraZeneca, has now added Johnson & Johnson to this list. The J&J deal, which could bring in up to $835 million plus royalties for Isis, covers the discovery and development of antisense drugs for autoimmune disorders in the gastrointestinal tract. Isis’ shares were up 10.7% on the announcement and hit a 52-week high as well (Read more: Isis Pharmaceuticals Up on Collaboration with J&J).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on KITE - FREE
Get the full Report on ISIS - FREE
Get the full Report on ALKS - FREE
Get the full Report on AMGN - FREE
Get the full Report on BIIB - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
KITE PHARMA INC (KITE): Free Stock Analysis Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis Report
ALKERMES INC (ALKS): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
To read this article on Zacks.com click here.